Chronic vasodilator therapy with flosequinan in <font color="blue">congestive_2</font> <font color="blue">heart_2</font> <font color="blue">failure_2</font> <font color="blue">._2</font> 
<br>
<br> This study was conducted to determine the long - term effect of flosequinan , a new orally administered arterial and venous dilator , on the clinical course of <font color="blue">patients_5</font> <font color="blue">with_5</font> <font color="blue">moderate_5</font> <font color="blue">to_5</font> <font color="blue">severe_5</font> <font color="blue">congestive_5</font> <font color="blue">heart_5</font> <font color="blue">failure_5</font> <font color="blue">._5</font> <font color="blue">Seventeen_6</font> <font color="blue">patients_6</font> <font color="blue">on_6</font> <font color="blue">chronic_6</font> <font color="blue">digitalis_6</font> <font color="blue">and_6</font> <font color="blue">diuretic_6</font> <font color="blue">therapy_6</font> were randomized to receive either flosequinan ( n = 9 ) or placebo ( n = 8) in a double - blind fashion . Changes in symptomatology , exercise performance , and left ventricular function were assessed serially during the <font color="blue">two_1</font> <font color="blue">-_1</font> <font color="blue">month_1</font> <font color="blue">treatment_1</font> <font color="blue">period_1</font> <font color="blue">._1</font> During the course of therapy , a modest improvement in the symptom scores and functional classification of the <font color="blue">flosequinan_2</font> <font color="blue">-_2</font> <font color="blue">treated_2</font> <font color="blue">patients_2</font> was observed . Flosequinan evoked a significant increase in maximal exercise capacity . While long - term flosequinan administration also effected a progressive increase in resting heart rate , it did not consistently improve indices of left ventricular systolic function . The addition of chronic vasodilator therapy with flosequinan to standard digitalis - diuretic regimens is capable of inducing clinical improvement in <font color="blue">patients_3</font> <font color="blue">with_2</font> <font color="blue">moderate_2</font> <font color="blue">to_2</font> <font color="blue">severe_2</font> <font color="blue">chronic_2</font> <font color="blue">heart_2</font> <font color="blue">failure_2</font> <font color="blue">._2</font> Trials involving larger <font color="blue">patient_1</font> <font color="blue">populations_1</font> will be necessary to confirm the results of this preliminary study and to determine the extent of clinical improvement , subpopulations benefited , role in heart failure therapeutics , and so forth .